AI Summary
MaxCyte reported $6.8 million total revenue for Q3 2025. Core business revenue declined by 21% compared to 2024. The company reiterated its 2025 revenue guidance. 77% gross margin reported, non-GAAP adjusted gross margin at 81%. One new strategic license client added, totaling 32 licenses now.
Sentiment Rationale
Revenue decline signals performance issues; similar trends previously impacted stock price.
Trading Thesis
Immediate financial outlook is affected, with possible market reaction post-earnings call.
Market-Moving
- MaxCyte reported $6.8 million total revenue for Q3 2025.
- Core business revenue declined by 21% compared to 2024.
- The company reiterated its 2025 revenue guidance.
Key Facts
- MaxCyte reported $6.8 million total revenue for Q3 2025.
- Core business revenue declined by 21% compared to 2024.
- The company reiterated its 2025 revenue guidance.
- 77% gross margin reported, non-GAAP adjusted gross margin at 81%.
- One new strategic license client added, totaling 32 licenses now.
Companies Mentioned
- ADIC (ADIC)
- ANOC (ANOC)
Earnings
Significant revenue decline and financial guidance direct nexus to MXCT performance.